Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Non-Current Assets: 2020-2024

Historic Non-Current Assets for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $1.6 million.

  • Mereo BioPharma Group's Non-Current Assets fell 40.93% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 40.93%. This contributed to the annual value of $1.6 million for FY2024, which is 40.60% down from last year.
  • As of FY2024, Mereo BioPharma Group's Non-Current Assets stood at $1.6 million, which was down 40.60% from $2.7 million recorded in FY2023.
  • Mereo BioPharma Group's Non-Current Assets' 5-year high stood at $42.7 million during FY2020, with a 5-year trough of $1.6 million in FY2024.
  • Its 3-year average for Non-Current Assets is $2.2 million, with a median of $2.2 million in 2022.
  • As far as peak fluctuations go, Mereo BioPharma Group's Non-Current Assets slumped by 93.93% in 2022, and later climbed by 23.60% in 2023.
  • Mereo BioPharma Group's Non-Current Assets (Yearly) stood at $42.7 million in 2020, then declined by 14.39% to $36.5 million in 2021, then tumbled by 93.93% to $2.2 million in 2022, then increased by 23.60% to $2.7 million in 2023, then plummeted by 40.60% to $1.6 million in 2024.